Clinical trial software for San Francisco Bay Area biotech

The Bay Area’s strength is the density of people and capital. South San Francisco describes itself as one of the largest biotech clusters in the world, and the surrounding cities add university spin-outs from UCSF, Stanford and Berkeley, tools and diagnostics companies and venture investors who fund a programme in stages. The result is a common pattern: a company with a strong asset, a modest clinical team and a milestone that requires a clinical dataset within a year. Clinical operations is often one head of clinical development, a clinical project manager and an outside CRO or consultant.

In that setting, the EDC decision is rarely a long evaluation. It is made by whoever has to deliver the first study, usually with a protocol that is still being revised and a site that wants forms to review. What matters is time to a working study and the ability to change it. A free sandbox, an AI draft of visits and forms from the protocol, and approved forms that lock for live use mean the build can follow the protocol rather than trail it. For first-in-human work specifically, see EDC for first-in-human studies, EDC for Phase 1 trials and best EDC systems for Phase 1 trials.

The risk is the opposite of slowness: a lean team that moves fast can forget governance. Decide early who approves form changes, who sees unblinded data if the study is blinded, and how safety information flows to the sponsor medical monitor. Role-based access, blinded roles enforced at the database layer and a field-level audit trail handle the mechanics; the decisions are yours.

A US-sponsored drug or biologic study typically runs under an IND with FDA, with ethics review by an institutional or commercial IRB, and the data system sits under the sponsor’s 21 CFR Part 11 responsibilities. Capture provides Part 11-aligned controls (audit trail, e-signatures, access control), but validated use is a shared responsibility and your quality documents carry that. For academic sponsors see the FDA IND application guide for academics, which is also useful for a spin-out’s first filing.

California adds its own state-level privacy and health-information rules on top of HIPAA at clinical sites. How those apply to research data, including the treatment of data collected in clinical trials, is a question for your counsel and privacy officer, and the same is true for any company that also enrols participants in Europe, where GDPR applies. Capture’s infrastructure is described as HIPAA-ready and GDPR-ready; read HIPAA vs GDPR for clinical trial data before you decide where data should live.

If the programme is a cell or gene therapy, a stem-cell funding programme such as California’s CIRM may be part of the picture, with its own reporting expectations. Check the current terms with the funder; the cell and gene therapy EDC page covers the data structure those studies need.